1503 related articles for article (PubMed ID: 16242629)
1. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
[TBL] [Abstract][Full Text] [Related]
2. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
[TBL] [Abstract][Full Text] [Related]
3. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
4. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Lastres-Becker I; de Miguel R; De Petrocellis L; Makriyannis A; Di Marzo V; Fernández-Ruiz J
J Neurochem; 2003 Mar; 84(5):1097-109. PubMed ID: 12603833
[TBL] [Abstract][Full Text] [Related]
5. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications.
Tzavara ET; Li DL; Moutsimilli L; Bisogno T; Di Marzo V; Phebus LA; Nomikos GG; Giros B
Biol Psychiatry; 2006 Mar; 59(6):508-15. PubMed ID: 16199010
[TBL] [Abstract][Full Text] [Related]
6. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence.
de Lago E; de Miguel R; Lastres-Becker I; Ramos JA; Fernández-Ruiz J
Brain Res; 2004 May; 1007(1-2):152-9. PubMed ID: 15064146
[TBL] [Abstract][Full Text] [Related]
7. Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems.
Micale V; Cristino L; Tamburella A; Petrosino S; Leggio GM; Drago F; Di Marzo V
Neurobiol Dis; 2009 Oct; 36(1):70-80. PubMed ID: 19591935
[TBL] [Abstract][Full Text] [Related]
8. Transient receptor potential vanilloid 1 channels control acetylcholine/2-arachidonoylglicerol coupling in the striatum.
Musella A; De Chiara V; Rossi S; Cavasinni F; Castelli M; Cantarella C; Mataluni G; Bernardi G; Centonze D
Neuroscience; 2010 May; 167(3):864-71. PubMed ID: 20219639
[TBL] [Abstract][Full Text] [Related]
9. The anandamide transport inhibitor AM404 reduces ethanol self-administration.
Cippitelli A; Bilbao A; Gorriti MA; Navarro M; Massi M; Piomelli D; Ciccocioppo R; Rodríguez de Fonseca F
Eur J Neurosci; 2007 Jul; 26(2):476-86. PubMed ID: 17650118
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the endocannabinoid system in human spermatozoa and involvement of transient receptor potential vanilloid 1 receptor in their fertilizing ability.
Francavilla F; Battista N; Barbonetti A; Vassallo MR; Rapino C; Antonangelo C; Pasquariello N; Catanzaro G; Barboni B; Maccarrone M
Endocrinology; 2009 Oct; 150(10):4692-700. PubMed ID: 19608651
[TBL] [Abstract][Full Text] [Related]
11. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis.
Centonze D; Bari M; Rossi S; Prosperetti C; Furlan R; Fezza F; De Chiara V; Battistini L; Bernardi G; Bernardini S; Martino G; Maccarrone M
Brain; 2007 Oct; 130(Pt 10):2543-53. PubMed ID: 17626034
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat.
Hong S; Fan J; Kemmerer ES; Evans S; Li Y; Wiley JW
Gut; 2009 Feb; 58(2):202-10. PubMed ID: 18936104
[TBL] [Abstract][Full Text] [Related]
13. The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain.
Malek N; Kostrzewa M; Makuch W; Pajak A; Kucharczyk M; Piscitelli F; Przewlocka B; Di Marzo V; Starowicz K
Pharmacol Res; 2016 Sep; 111():251-263. PubMed ID: 27326920
[TBL] [Abstract][Full Text] [Related]
14. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
de Lago E; Fernández-Ruiz J; Ortega-Gutiérrez S; Cabranes A; Pryce G; Baker D; López-Rodríguez M; Ramos JA
Eur Neuropsychopharmacol; 2006 Jan; 16(1):7-18. PubMed ID: 16006105
[TBL] [Abstract][Full Text] [Related]
15. Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats.
Nucci C; Gasperi V; Tartaglione R; Cerulli A; Terrinoni A; Bari M; De Simone C; Agrò AF; Morrone LA; Corasaniti MT; Bagetta G; Maccarrone M
Invest Ophthalmol Vis Sci; 2007 Jul; 48(7):2997-3004. PubMed ID: 17591864
[TBL] [Abstract][Full Text] [Related]
16. The endogenous cannabinoid anandamide inhibits transient receptor potential vanilloid type 1 receptor-mediated currents in rat cultured primary sensory neurons.
Sántha P; Jenes A; Somogyi C; Nagy I
Acta Physiol Hung; 2010 Jun; 97(2):149-58. PubMed ID: 20511124
[TBL] [Abstract][Full Text] [Related]
17. N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors.
Marinelli S; Di Marzo V; Florenzano F; Fezza F; Viscomi MT; van der Stelt M; Bernardi G; Molinari M; Maccarrone M; Mercuri NB
Neuropsychopharmacology; 2007 Feb; 32(2):298-308. PubMed ID: 16760924
[TBL] [Abstract][Full Text] [Related]
18. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol.
Spoto B; Fezza F; Parlongo G; Battista N; Sgro' E; Gasperi V; Zoccali C; Maccarrone M
Biochimie; 2006 Dec; 88(12):1889-97. PubMed ID: 16949718
[TBL] [Abstract][Full Text] [Related]
19. Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit.
Almeida V; Levin R; Peres FF; Suiama MA; Vendramini AM; Santos CM; Silva ND; Zuardi AW; Hallak JEC; Crippa JA; Abílio VC
Neuropharmacology; 2019 Sep; 155():44-53. PubMed ID: 31103618
[TBL] [Abstract][Full Text] [Related]
20. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.
Di Marzo V; Hill MP; Bisogno T; Crossman AR; Brotchie JM
FASEB J; 2000 Jul; 14(10):1432-8. PubMed ID: 10877836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
